Vical competitors

George Lemaitre is a Chairman/CEO at LEMAITRE VASCULAR INC, Manager at Lemaitre Family LLC, and Board Member at VASCUTECH INC and is based in Greater Boston Area. He has worked as Board Member at LEMAITRE VASCULAR INC, Credit Analyst at Connecticut National Bank/Bridgeport CT, and Associate at MCCOWN DE LEEUW & CO. George works or has worked as Board of Directors at LEMAITRE VASCULAR INC, Owner at LEMAITRE VASCULAR INC, and BOARD MEMBER at Stanford Univ Graduate Schl of Bussiness Management. He attended Stanford Graduate School of Business between 1990 and 1992, Phillips Academy Andover between 1978 and 1982, and Stanford University between 1982 and 1986.

Michael Castagna is a Board Member at MANNKIND CORP and Chief Executive Officer at MANNKIND CORP and is based in Westlake Village, California. He has worked as Vice President & Head, Biopharmaceuticals North America at Sandoz; Director, Endocrinology Marketing at Healthcare Business of Merck; and VP/Global Head:Commercial at Amgen. Michael attended Massachusetts College of Pharmacy and Health Sciences between 2012 and 2014, The Wharton School between 2003 and 2005, and Philadelphia College of Pharmacy & Science.

Chief Executive Officer and member of the board of XOMA (NASDAQ: XOMA). Joined XOMA in 2009 and was appointed to the CEO role in late 2016. In early 2017, Mr. Neal led XOMA through a dramatic strategic pivot taking the company from a traditional R&D heavy biotech company and transforming it to a successful royalty monetization and aggregation company. In the years prior to becoming CEO of XOMA, he was instrumental in leading the company’s licensing and business development activities focused on maximizing the value of XOMA’s foundational antibody IP and knowhow. In addition to his role at XOMA, Mr. Neal currently serves as a Director at Leading Biosciences, a clinical stage biotech company based in Carlsbad, CA. Mr. Neal has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Prior to XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos Inc., a leading bio-simulation company that acquired Iconix Biosciences, a privately held company where Mr. Neal was Chief Executive Officer. At Iconix, Mr. Neal established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs (now AbbVie), Eli Lilly and the U.S. Food and Drug Administration. From 1999-2002, he was Executive Vice President of Incyte Genomics, leading global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis, GSK and others. Earlier in his career, he was an executive with Monsanto Company in positions of increasing responsibility. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an MBA degree from Washington University in St. Louis, MO.

Rick Hancock is a Chairman at Argonaut Manufacturing Services Inc, Board Member at Tempo Therapeutics, and Executive Board Member at Argonaut Manufacturing Services Inc and is based in San Diego, California. He has experience at Hybritech and Genetics Institute and has worked as Chief Operating Officer at ALTHEA TECHNOLOGIES INC and Interim President and CEO at AVID BIOSERVICES, INC.. Rick works or has worked at Orchestra Therapeutics Inc and works or has worked as Exec VP:Europe at ALTHEA TECHNOLOGIES INC. He attended Miami University between 1975 and 1980.

Dennis Eastburn is a Chief Executive Officer, Co-founder at Barrier Biopharma, Inc. and is based in San Francisco, California. He has worked as Postdoctoral Fellow at University of California San Francisco; Consultant at ARDELYX, INC.; and Chief Scientific Officer, Co-founder at Mission Bio. Dennis studied at The University of Texas at Austin between 1993 and 1997 and University of Colorado Boulder between 1998 and 2004.

Stephen Turner is Chief Executive Officer and Chairman of the Board, positions he has held since founding the company in July, 2001. From 1999 to 2001 he served as President and CEO of Quorum Sciences, Inc. From 1984 to 1997 he was President and CEO of Oncor, Inc. He founded Bethesda Research Laboratories, Inc. in 1975 and served as its Chairman and CEO from 1975 to 1983, at which time BRL became the molecular biology division of Life Technologies, Inc. Prior to commencing his career in biotechnology, Mr. Turner held the position of Director of Marketing for the Clinical Microbiology Division of Becton, Dickinson & Co. He received his B.A. from Stanford University in 1967. In 1994 he received the Ernst & Young Entrepreneur of the Year Award in Life Sciences for the Washington D.C. Region.